The pandemic situation with the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from China has endangered human lives. Coronavirus disease 2019 (COVID-19) is presented with asymptomatic, mild, or severe pneumonia-like symptoms. COVID-19 patients with diabetes, chronic obstructive pulmonary disease (COPD), cardiovascular diseases (CVD), hypertension, malignancies, HIV, and other comorbidities could develop a life-threatening situation. SARS-CoV-2 utilizes ACE-2 receptors found at the surface of the host cells to get inside the cell. Certain comorbidities are associated with a strong ACE-2 receptor expression and higher release of proprotein convertase that enhances the viral entry into the host cells. The comorbidities lead to the COVID-19 patient into a vicious infectious circle of life and are substantially associated with significant morbidity and mortality. The comorbid individuals must adopt the vigilant preventive measure and require scrupulous management. In this review, we rigorously focused on the impact of common morbidities in COVID-19 patients and recapitulated the management strategies with recent directions. We found limited resources describing the association of comorbidities in COVID-19; however, our review delineates the broader spectrum of comorbidities with COVID-19 patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402107 | PMC |
http://dx.doi.org/10.1016/j.jiph.2020.07.014 | DOI Listing |
Alzheimers Dement
December 2024
Tulane University, New Orleans, LA, USA.
Background: Vascular dementia (VaD), the second most common cause of dementia, is characterized by cognitive decline due to reduced cerebral blood flow and blood-brain barrier disruption. Current evidence demonstrates that not only are VaD patients at higher risk of severe COVID-19 illness and mortality, but also that pre-existing cognitive dysfunction/dementia is associated with increased COVID-19 incidence. Conversely, SARS-CoV-2 infection alone worsens dementia-related mild cognitive impairment (MCI) and increases risk of cognitive decline, supported by similar fMRI findings demonstrating hypoperfusion.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
UOC Geriatria - Disturbi Cognitivi e Demenza; AUSL Modena, Modena, Italy.
Background: Social restrictions and closures of services due to COVID-19 pandemic had a negative impact on the social inclusion and well-being of older people. In fact, older adults present risk factors both in terms of health - such as frailty or multimorbidity - and in terms of quality of life - for example institutionalization - and poor social support. The main objective is to evaluate whether social support had the role of an effect modifier on the incidence of cognitive frailty.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
CIUSSS de L'Estrie-CHUS, Sherbrooke, QC, Canada.
Background: In the province of Quebec, Canada, primary care management of Alzheimer's disease is provided by the Family Medicine Group with the support of the Ministerial Initiative on Alzheimer's Disease and the collaboration of specialized memory clinics. The COVID years have severely strained health resources in all areas, including cognitive intervention resources. We describe the reorganization of regional support in the Eastern Townships.
View Article and Find Full Text PDFClin Nurs Res
January 2025
Institute of Human Genetics, Faculty of Medicine, University of Belgrade, Serbia.
The hypoxia-inducible factor-1 alpha (HIF-1 alpha) is a major regulator of adaptive response to hypoxia, common in patients with severe coronavirus disease 2019 (COVID-19). In addition, HIF-1 alpha regulates the expression of the most important proteins necessary for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of cells. The study included 129 hospitalized COVID-19 patients.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Davos Alzheimer's Collaborative, Wayne, PA, USA.
Background: Cognitive impairment is frequently undetected or undiagnosed in the early stages. To increase the rates of detecting cognitive impairment, the Early Detection program of the Davos Alzheimer's Collaborative System Preparedness (DAC-SP) implemented digital cognitive assessments (DCA) in primary care and other non-specialty settings.
Methods: The DAC-SP Early Detection program was initiated in 2021 in seven healthcare systems across six countries.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!